PURPOSE: Merkel cell carcinoma (MCC) is an uncommon cutaneous malignancy. Most reports consist of single-institution experiences of fewer than 30 patients. The natural history of MCC is poorly defined. PATIENTS AND METHODS: A review was performed of Memorial Sloan-Kettering Cancer Center's MCC database, identifying 251 patients who had been treated between 1970 and 2002. Patient, tumor, and treatment-related factors were analyzed for their association with recurrence and survival. RESULTS: The average follow-up for all patients was 40 months and 46 months for patients alive at last follow-up. The 5-year disease-specific survival rate was 64%. Disease stage was the only independent predictor of survival (stage I, 81%; stage II, 67%; stage III, 52%; stage IV, 11%; P = .001). Pathologic staging of the draining nodal basin was performed in 71 (40%) of 177 patients who presented with clinically negative nodes, and 16 of these patients (23%) were found to have node-positive disease. Pathologic nodal staging was associated with improved stage-specific survival probabilities (clinical node-negative, 75% v pathologic node-negative disease, 97%; P = .009) and decreased nodal recurrence (44% v 11%, P < .001). The median time to recurrence was 9 months, and 102 patients (43%) recurred. Local recurrence developed in 8% of patients after margin-negative excision. CONCLUSION: These data demonstrate that the natural history of MCC is variable and dependent on the stage of disease at presentation. Pathologic nodal staging identifies a group of patients with excellent long-term survival. After margin-negative excision and pathologic nodal staging, local and nodal recurrence rates are low.
PURPOSE:Merkel cell carcinoma (MCC) is an uncommon cutaneous malignancy. Most reports consist of single-institution experiences of fewer than 30 patients. The natural history of MCC is poorly defined. PATIENTS AND METHODS: A review was performed of Memorial Sloan-Kettering Cancer Center's MCC database, identifying 251 patients who had been treated between 1970 and 2002. Patient, tumor, and treatment-related factors were analyzed for their association with recurrence and survival. RESULTS: The average follow-up for all patients was 40 months and 46 months for patients alive at last follow-up. The 5-year disease-specific survival rate was 64%. Disease stage was the only independent predictor of survival (stage I, 81%; stage II, 67%; stage III, 52%; stage IV, 11%; P = .001). Pathologic staging of the draining nodal basin was performed in 71 (40%) of 177 patients who presented with clinically negative nodes, and 16 of these patients (23%) were found to have node-positive disease. Pathologic nodal staging was associated with improved stage-specific survival probabilities (clinical node-negative, 75% v pathologic node-negative disease, 97%; P = .009) and decreased nodal recurrence (44% v 11%, P < .001). The median time to recurrence was 9 months, and 102 patients (43%) recurred. Local recurrence developed in 8% of patients after margin-negative excision. CONCLUSION: These data demonstrate that the natural history of MCC is variable and dependent on the stage of disease at presentation. Pathologic nodal staging identifies a group of patients with excellent long-term survival. After margin-negative excision and pathologic nodal staging, local and nodal recurrence rates are low.
Authors: Kathrin Gessner; Gunnar Wichmann; Andreas Boehm; Anett Reiche; Julia Bertolini; Johannes Brus; Ina Sterker; Stefan Dietzsch; Andreas Dietz Journal: Eur Arch Otorhinolaryngol Date: 2010-08-27 Impact factor: 2.503
Authors: Bianca D Lemos; Barry E Storer; Jayasri G Iyer; Jerri Linn Phillips; Christopher K Bichakjian; L Christine Fang; Timothy M Johnson; Nanette J Liegeois-Kwon; Clark C Otley; Kelly G Paulson; Merrick I Ross; Siegrid S Yu; Nathalie C Zeitouni; David R Byrd; Vernon K Sondak; Jeffrey E Gershenwald; Arthur J Sober; Paul Nghiem Journal: J Am Acad Dermatol Date: 2010-06-19 Impact factor: 11.527
Authors: Rocio Garcia-Carbonero; Ivan Marquez-Rodas; Luis de la Cruz-Merino; Javier Martinez-Trufero; Miguel Angel Cabrera; Jose Maria Piulats; Jaume Capdevila; Enrique Grande; Salvador Martin-Algarra; Alfonso Berrocal Journal: Oncologist Date: 2019-04-08
Authors: Jeremiah L Deneve; Jane L Messina; Suroosh S Marzban; Ricardo J Gonzalez; Brooke M Walls; Kate J Fisher; Y Ann Chen; C Wayne Cruse; Vernon K Sondak; Jonathan S Zager Journal: Ann Surg Oncol Date: 2012-01-21 Impact factor: 5.344
Authors: Matthew C Perez; Felipe R de Pinho; Amanda Holstein; Daniel E Oliver; Syeda M H Naqvi; Youngchul Kim; Jane L Messina; Erin Burke; Ricardo J Gonzalez; Amod A Sarnaik; C Wayne Cruse; Evan J Wuthrick; Louis B Harrison; Vernon K Sondak; Jonathan S Zager Journal: Ann Surg Oncol Date: 2018-08-02 Impact factor: 5.344
Authors: Wolfram E Samlowski; James Moon; Ralph J Tuthill; Michael C Heinrich; Naomi S Balzer-Haas; Stuart A Merl; Ronald C DeConti; John A Thompson; Merle T Witter; Lawrence E Flaherty; Vernon K Sondak Journal: Am J Clin Oncol Date: 2010-10 Impact factor: 2.339